Mycosis fungoides tied to excess risk for second primary cancer

  • Goyal A & al.
  • J Am Acad Dermatol
  • 30 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Mycosis fungoides (MF) is associated with increased risk for second primary hematologic and solid malignancies, according to analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Why this matters

  • These study results suggest a need for increased screening for second primary malignancies in patients with MF.

Key results

  • 7.5% of patients were diagnosed with a second malignancy.
  • Patients with MF were at increased risk for second cancer events (standardized incidence ratio [SIR], 10.15; 95% CI, 9.29-11.07; P<.05 style="list-style-type:circle;">
  • SIR, 39.71 (95% CI, 34.05-46.05; P<.05 for hematologic malignancies.>
  • SIR, 7.33 (95% CI, 6.56-8.17; P<.05 for solid tumor malignancies.>
  • Female patients had higher risk than male patients (SIR, 13.95 vs 8.62; P<.033>
  • Patients with second malignancies had worse age-adjusted OS compared with those without second malignancy (HR, 2.72; P<.001>

    Study design

    • 6742 patients with MF from the SEER database were included.
    • Funding: American Society of Hematology; NIH.

    Limitations

    • Retrospective study of large database.